The FDA has approved the generic drug application (ANDA 210449) for Apotex, authorizing the manufacturer to launch a cost-effective alternative to the branded treatment. This approval poises Apotex to introduce significant market competition, likely reducing therapeutic costs and increasing patient access once the product captures its 180-day exclusivity.